Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
This article was originally published in The Gray Sheet
Executive Summary
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded